PCOS is a commonly encountered endocrinopathy in women of reproductive age
Providers need to appreciate that the syndrome is associated with significant morbidity in terms of reproductive as well as nonreproductive events
Recognize these patients
Use precautionary measures to prevent cardiovascular disease and type 2 diabetes
Apridonidze T., Essah P., Iuorno M., Nestler J. Prevalence and characteristics of the
metabolic syndrome in women with polycystic ovary syndrome. The Journal of Clinical Endrocrinology and Metabolism. 2005; 90(4):1929-1935.
Carmina E., Lobo R., Polycystic ovary syndrome (PCOS): Arguably the most common
endocrinopathy is associated with significant morbidity in women. The Journal of
Clinical Endocrinology and Metabolism 1999; 84(6):1897-1899.
Dunaif A., Scott D., Finegood D., Quintana B., Whitcomb R. The insulin-sensitizing
agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism. 1996; 81(9):3299-3306.
Ehrmann D., Liljenquist D., Kasza K., Azziz R., Legro R., Ghazzi M. Prevalence and
predictors of the metabolic syndrome in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism. 2006; 91(1): 48-53.
Flegal et. al. CDC, National Center for Health Statistics, National Health and Nutrition
survery. JAMA. 2002;288: 1723-1727
Glueck C.J., Papanna R., Wang P., Goldenberg N., Sieve-Smith L. Incidence and
treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism. 2003; 52(7);908-915.
Hopkinson Z., Sattar N., Fleming R., Greer I. Polycystic ovarian syndrome: the
metabolic syndrome comes to gynaecology. BMJ. 1998; 317:329-332.
Kendall D., Harmel A. The metabolic syndrome, type 2 diabetes, and cardiovascular
disease: understanding the role of insulin resistance. The Amecican Journal Of Managed Care. 2002; 8(20): 635-653.
Marx T. Mehta E. Polycystic ovary syndrome: Pathogenesis and treatment over the
short and long term. Cleveland Clinic Journal of Medicine. 2003;70(1).
Moghetti P., Castello R., Negri C., Tosi F., Perrone F., Caputo M., et al. Metformin
effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. The Journal of Clinical Endocrinolgy and Metabolism. 2000; 85(1): 139-146.
Morin-Papunen L., Vauhdonen I., Koivunen R., Ruokonen A., Martikainen H.,
Tapanainen R., et al. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endrocrinology and Metabolism. 2000; 85(9): 3161-3168.
Sheehan M. Polycystic ovarian syndrome: diagnosis and management. Clinical
Medicine and Research. 2004; 2(1); 13-27.
Sharpless JL., Polycystic ovary syndrome and the metabolic syndrome. Clinical
Diabetes. 2003; 21(4) 154-161.
Volek J., Feinman R., Carbohydrate restriction improves the features of metabolic
syndrome. Metabolic syndrome may be defined by the response to carbohydrate restriction. Nutrition and Metabolism. 2005; 2(31).
Vural B., Caliskan E., Turkoz E., Kilic T., Demirci A. Evaluation of metabolic
syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Human Reproduction. 2005; 20(9): 2409-2413.
Zoe E. C. Hopkinson, Naveed Sattar, Richard Fleming, Ian A. Greer, Polycystic
ovarian syndrome: the metabolic syndrome comes to gynaecology. BMJ. 1998; 317: 329-332)